

## PRESS RELEASE

---

# Invitation to Camurus' Capital Markets and R&D Day 6 September 2022

**Lund, Sweden — 10 June 2022** — Camurus (NASDAQ STO: CAMX) invites investors, analysts and media to a Capital Markets and R&D Day on 6 September 2022 in Stockholm, Sweden.

During the event, members of Camurus' senior management will provide an update on the company strategy, business progress and key R&D pipeline programs. Further insights will be provided by leading clinical experts within Camurus' therapeutic focus areas.

Time: Tuesday 6 September 2022, 1 pm – 5 pm CET

Venue: IVA Conference Center, Grev Turegatan 16, Stockholm

### Registration for analysts, investors, and journalists

To participate, please register no later than 30 August at [CMD@camurus.com](mailto:CMD@camurus.com).

A detailed program will be provided at Camurus website [www.camurus.com](http://www.camurus.com) two weeks ahead of the event.

### For more information

Fredrik Tiberg, President & CEO, Head R&D

Tel. +46 (0)46 286 46 92

[fredrik.tiberg@camurus.com](mailto:fredrik.tiberg@camurus.com)

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

[ir@camurus.com](mailto:ir@camurus.com)

### About Camurus

*Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [www.camurus.com](http://www.camurus.com).*

This information was submitted for publication at 8:00 am CET on 10 June 2022.